Antipsychotic-Induced Insulin Resistance and Postprandial Hormonal Dysregulation Independent of Weight Gain or Psychiatric Disease
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Atypical antipsychotic (AAP) medications that have revolutionized the treatment of mental illness have become stigmatized by metabolic side effects, including obesity and diabetes. It remains controversial whether the defects are treatment induced or disease related. Although the mechanisms underlying these metabolic defects are not understood, it is assumed that the initiating pathophysiology is weight gain, secondary to centrally mediated increases in appetite. To determine if the AAPs have detrimental metabolic effects independent of weight gain or psychiatric disease, we administered olanzapine, aripiprazole, or placebo for 9 days to healthy subjects (n = 10, each group) under controlled in-patient conditions while maintaining activity levels. Prior to and after the interventions, we conducted a meal challenge and a euglycemic-hyperinsulinemic clamp to evaluate insulin sensitivity and glucose disposal. We found that olanzapine, an AAP highly associated with weight gain, causes significant elevations in postprandial insulin, glucagon-like peptide 1 (GLP-1), and glucagon coincident with insulin resistance compared with placebo. Aripiprazole, an AAP considered metabolically sparing, induces insulin resistance but has no effect on postprandial hormones. Importantly, the metabolic changes occur in the absence of weight gain, increases in food intake and hunger, or psychiatric disease, suggesting that AAPs exert direct effects on tissues independent of mechanisms regulating eating behavior.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In psychiatry, iatrogenesis has traditionally been concerned with medical complications of psychotropic drug treatment [3], such as tardive dyskinesia [4] and insulin resistance [5] with antipsychotic drugs, and cardiac and metabolic disturbances with antidepressant medications [6][7][8].”
From Iatrogenic Factors in Psychopathology (2019) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
(1998) · PubMed · Cited by 10,216
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,872
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · cited 2×
“Over the past decade, there has been increasing recognition that some of the second-generation antipsychotic medications, termed the atypical antipsychotics (AAPs), are associated with an increased incidence of obesity (1), type 2 diabetes (2,3), and cardiovascular disease (4,5).”
BackgroundThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 2×
“However, elevations in GLP-1 coincident with insulin resistance and increases in glucagon are surprising since GLP-1 inhibits glucagon release (37) and is attenuated in type 2 diabetes (38).”
BackgroundMcEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., Meltzer, H. Y., Hsiao, J., Scott Stroup, T., & Lieberman, J. A. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,140 · cited 1×
“Aripiprazole tends to cause less weight gain than olanzapine (15) and is often considered metabolically neutral (16–18).”
BackgroundAssessment of Insulin Sensitivity in Vivo*
Bergman, R. N., Finegood, D. T., & Ader, M. (1985) · Endocrine Reviews · doi:10.1210/edrv-6-1-45 · Cited by 1,066 · cited 8×
“Preintervention, postprandial glucose levels were not significantly different across treatments (F(2,27) = 0.”
BackgroundResultInfluentialCorrell, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050 · cited 1×
“The implications for public health are tremendous (6) due to the large number of adult patients treated with these agents and the increasing use of off-label prescriptions to children (7) and the elderly (8).”
BackgroundVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884 · cited 1×
“However, elevations in GLP-1 coincident with insulin resistance and increases in glucagon are surprising since GLP-1 inhibits glucagon release (37) and is attenuated in type 2 diabetes (38).”
BackgroundGlucocorticoids and insulin resistance: old hormones, new targets
ANDREWS, R. C., & WALKER, B. R. (1999) · Clinical Science · doi:10.1042/cs0960513 · Cited by 731 · cited 1×
“Two important variables that will be measured in future studies are glucose-dependent insulinotropic peptide, known to enhance insulin secretion (47), and cortisol, which can induce insulin resistance (48).”
Background
Cited by
Items 101–200 of 200
Type 2 Diabetes in Children and Adolescents on Atypical Antipsychotics
Pramyothin, P., & Khaodhiar, L. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0623-4 · Cited by 19
Happell, B., Stanton, R., Platania‐Phung, C., McKenna, B., & Scott, D. S. (2014) · Issues in Mental Health Nursing · doi:10.3109/01612840.2014.896061 · Cited by 18
“, 2012), increased insulin sensitivity (Teff et al., 2013), altered lipid profile (Watanabe, Suzuki, & Someya, 2012) and changes in cardiac electrophysiology (Linzer et al.”
BackgroundThe Probiotic Mixture VSL#3 Reverses Olanzapine-Induced Metabolic Dysfunction in Mice
Dhaliwal, N., Dhaliwal, J., Singh, D. P., Kondepudi, K. K., Bishnoi, M., & Chopra, K. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9554-7_31 · Cited by 16
Pancreas and Adverse Drug Reactions: A Literature Review
Sosnowski, K., Nehring, P., & Przybyłkowski, A. M. (2022) · Drug Safety · doi:10.1007/s40264-022-01204-0 · Cited by 15
“Interestingly, studies suggest that glucose metabolism may be impaired before SGA-induced weight gain [103, 104].”
BackgroundGLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
Horská, K., Kučerová, J., & Skrede, S. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.06.005 · Cited by 14
Stefanidis, A., Watt, M. J., Cowley, M. A., & Oldfield, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.010 · Cited by 15
“The most parsimonious explanation of this increased predisposition to type 2 diabetes would be APD associated weight gain, however, a number of reports describe hyperglycemia following olanzapine treatment that is not associated with weight gain (Albaugh et al., 2011b; Teff et al., 2013).”
BackgroundInfluentialDoes the Time of Drug Administration Alter the Metabolic Risk of Aripiprazole?
Chipchura, D. A., Freyberg, Z., Edwards, C., Leckband, S. G., & McCarthy, M. J. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00494 · Cited by 15
“Even drugs considered “metabolically neutral” like aripiprazole (ARPZ) may promote glucose intolerance (8).”
BackgroundBrain stem as a target site for the metabolic side effects of olanzapine
Anwar, I. J., Miyata, K., & Zsombok, A. (2016) · Journal of Neurophysiology · doi:10.1152/jn.00387.2015 · Cited by 13
“Atypical antipsychotic medications including olanzapine have undesirable, well-described side effects involving weight gain, dyslipidemia, and impaired glucose homeostasis leading to the development of type 2 diabetes mellitus (Barnard et al. 2013; Chiu et al. 2010; Coccurello and Moles 2010; Teff et al. 2013).”
BackgroundAtypical antipsychotics and metabolic syndrome
Rodriguez, A. P., Tajima-Pozo, K., Lewczuk, A., & Rada, F. M. (2015) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000063 · Cited by 13
Vélez-Pérez, E., Raymond, N., Kiely, C., Molho, W., Trotti, R. L., Harris, C. A., Bannai, D., Hegde, R. R., Herold, S., Keshavan, M. S., et al. (2024) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2024.100088 · Cited by 11
“Although we did not identify significant differences in fERG amplitudes between antipsychotic-naïve participants and those on antipsychotics, prior studies have demonstrated that antipsychotics can influence retinal function in psychosis (Adámek et al., 2022; Deng, 2013; Teff et al., 2013).”
Li, H., Fang, M., Xu, M., Li, S., Du, J., Li, W., & Chen, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167930 · Cited by 12
Caravaggio, F., Brucato, G., Kegeles, L. S., Lehembre-Shiah, E., Arndt, L. Y., Colibazzi, T., & Girgis, R. R. (2017) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000736 · Cited by 11
“In healthy persons, acute (9-day) administration of olanzapine or aripiprazole can significantly increase IR in the absence of weight gain (Teff et al., 2013).”
BackgroundTeff, K. L., Rickels, K., Al-Shehabi, E., & Rickels, M. R. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000393 · Cited by 11
“These effects were shown to be independent of weight gain or changes in food intake.(16) Few studies have investigated detailed eating behaviors initially after drug administration, and it is not known how and when the SGAs influence food intake, hunger, and satiety during the early time period after starting treatmen…”
BackgroundMethodResultSelf-citationZhou, J., Guo, X., Liu, X., Luo, Y., Chang, X., He, H., Duan, M., Li, S., Li, Q., Tan, Y. H. V., et al. (2023) · Life · doi:10.3390/life13010144 · Cited by 10
“Antipsychotics could impact brain insulin signal and induce peripheral insulin resistance [41,66].”
BackgroundNutrition and schizophrenia: associations worthy of continued revaluation
Tang, M., Zhao, T., Liu, T. C., Dang, R., Cai, H., & Wang, Y. (2023) · Nutritional Neuroscience · doi:10.1080/1028415x.2023.2233176 · Cited by 10
“They noted that with prolonged olanzapine administration, SGAs could exacerbate metabolic e ff ects by mediating increases in food intake required for weight gain [68].”
BackgroundAtypical antipsychotic drugs cause abnormal glucose and lipid metabolism independent of weight gain
Yang, Y., & Wu, R. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-01965-6 · Cited by 10
“This supports the hypothesis that AAPs directly affect metabolism indepen - dently of weight gain and appetite-regulating mechanisms [31 ].”
Blanchard, E., & Samaras, K. (2014) · Diabetes Management · doi:10.2217/dmt.14.24 · Cited by 11
Kelly, J. R., Gounden, P., McLoughlin, A., Legris, Z., O’Carroll, T., McCafferty, R., Marques, L., Haran, M., Farrelly, R., Loughrey, K., et al. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02576-5 · Cited by 10
Piras, M., Ranjbar, S., Laaboub, N., Grosu, C., Gamma, F., Plessen, K. J., von Gunten, A., Conus, P., & Eap, C. B. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac133 · Cited by 10
Acute Metabolic Effects of Olanzapine Depend on Dose and Injection Site
Klingerman, C. M., Stipanovic, M. E., Hajnal, A. S., & Lynch, C. J. (2015) · Dose-Response · doi:10.1177/1559325815618915 · Cited by 10
Lemay, J.-F., Lanzinger, S., Pacaud, D., Plener, P. L., Fürst-Burger, A., Biester, T., Hilgard, D., Lilienthal, E., Galler, A., Berger, G., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12676 · Cited by 9
Braude, M. R., Con, D., Lubel, J. S., Bidwai, A., Nguyen, H.-T., Sharmamiglani, S., Clarke, D. M., Dev, A. T., & Sievert, W. (2021) · Hepatology International · doi:10.1007/s12072-021-10195-6 · Cited by 9
“1 3 and insulin resistance in healthy adults following short-term administration [22, 25].”
BackgroundSelf-citationAcute Hyperinsulinemia Alters Bone Turnover in Women and Men With Type 1 Diabetes
Sherk, V. D., Vigers, T., Pyle, L. L., Snell‐Bergeon, J. K., Nadeau, K. J., Rickels, M. R., Miller, K. M., Greenbaum, C. J., & Shah, V. N. (2020) · JBMR Plus · doi:10.1002/jbm4.10389 · Cited by 9
Self-citationUnraveling the Mechanisms Underlying Olanzapine-Induced Insulin Resistance
Irwin, N., & Gault, V. A. (2013) · Diabetes · doi:10.2337/db13-0804 · Cited by 9
“(2) was participant ingestion of a mixed meal that elicited both incretin responses (5) and neurally mediated insulin release (6), both of which could be critical for the metabolic effects of centrally acting drugs.”
BackgroundInfluentialBabic, I., Sellers, D., Else, P. L., Nealon, J. R., Osborne, A. L., Pai, N. B., & Weston–Green, K. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120981377 · Cited by 9
“Olanzapine can slightly elevate glucagon levels in humans (Teff et al., 2013); however, our findings that olanzapine did not cause hyperglycaemia or alter insulin coincides with the lack of change in glucagon levels.”
ResultInfluentialSchizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 9
Martínez-Pinteño, A., Gassó, P., Prohens, L., Segura, À. G., Parellada, M., Sáiz, P. A., Cuesta, M. J., Bernardo, M., Lafuente, A., Mas, S., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.729474 · Cited by 8
“…to be a prime factor leading to the development of hyperglycemia, impaired insulin levels and insulin resistance (Cao et al., 2017; Yao et al., 2018), which frequently occur in individuals treated with second-generation APs (Newcomer et al., 2002; Henderson et al., 2005; Teff et al., 2013).”
BackgroundDietary Fructose and GLUT5 Transporter Activity Contribute to Antipsychotic-Induced Weight Gain
Palavicino‐Maggio, C. B., & Kuzhikandathil, E. V. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw037 · Cited by 8
Khan, M. M., Khan, Z. A., & Khan, M. A. (2024) · World Journal of Psychiatry · doi:10.5498/wjp.v14.i6.767 · Cited by 7
Bonifazi, A., Ellenberger, M. P., Farino, Z. J., Aslanoglou, D., Rais, R., Pereira, S., Mantilla-Rivas, J. O., Boateng, C. A., Eshleman, A. J., Janowsky, A. J., et al. (2024) · Diabetes · doi:10.2337/db24-0175 · Cited by 7
Caravaggio, F., Iwata, Y., Plitman, E., Chavez, S., Borlido, C., Chung, J. K., Kim, J., Agarwal, S. M., Gerretsen, P., Remington, G. J., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.12.002 · Cited by 7
“Moreover, acute (9-day) administration of olanzapine or aripiprazole can significantly increase IR in the absence of weight gain (Teff et al., 2013) and some of this effect may indeed be due to central actions (Hahn et al., 2014; Michaelides et al., 2017).”
BackgroundTamaroff, J. G., Nguyen, S., Wilson, N. E., Stefanovski, D., Xiao, R., Scattergood, T. M., Capiola, C. J., Schur, G. M., Dunn, J., Dedio, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae545 · Cited by 6
Self-citationAu, E., Panganiban, K. J., Wu, S., Sun, K., Humber, B. E., Remington, G. J., Agarwal, S. M., Giacca, A., Pereira, S., & Hahn, M. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.10.001 · Cited by 9
Translational Aspects in Drug Discovery
Detalle, L., Vanheusden, K., Sargentini-Maier, M.-L., & Stöhr, T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12335-2 · Cited by 7
Akinlade, K. S., Rahamon, S. K., & Lasebikan, V. O. (2018) · Journal of the National Medical Association · doi:10.1016/j.jnma.2018.01.003 · Cited by 7
Alkholy, R., Lovell, K., Bee, P., Pedley, R., Brooks, H. L., Drake, R., Chitsabesan, P., Bhutta, A., Brown, A., Jenkins, R., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0308037 · Cited by 7
Burghardt, K. J., Burghardt, P. R., Howlett, B. H., Dass, S. E., Zahn, B., Imam, A. A., Mallisho, A., Msallaty, Z., Seyoum, B., & Yi, Z. (2024) · Biomedicines · doi:10.3390/biomedicines12051057 · Cited by 6
“This work has been continuously built upon with meta-analytic findings as well as deeper metabolic phenotyping, allowing for an in-depth investigation into the effect of antipsychotics on glucose regulation and insulin signaling [5,26–28].”
Wang, C., Wang, C., Ren, L., Chen, S., Chen, W., & Li, Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119037 · Cited by 5
Cardiometabolic Risk and Monitoring in Psychiatric Disorders
Samaras, K. (2016) · Springer eBooks · doi:10.1007/978-3-319-32480-7_18 · Cited by 6
Une approche de la psychopharmacologie des premiers épisodes psychotiques axée sur le rétablissement
Béchard, L., Corbeil, O., Malenfant, E., Lehoux, C., Stip, É., Roy, M., & Demers, M. (2021) · Santé mentale au Québec · doi:10.7202/1088180ar · Cited by 5
Analgesic and Anti-Inflammatory Effects of Phaseolus vulgaris L. Fixed Oil in Rodents
Salma, S., Baig, S. G., Hasan, M. M., Ahmed, S., & Fatima, S. (2018) · Journal of Basic & Applied Sciences · doi:10.6000/1927-5129.2018.14.26 · Cited by 5
“The latter mechanism suggest that ALA is helpful in preventing hypertension, CVD, diabetes type II and COPD [20].”
BackgroundFriedrich, M. E., Fugiel, J., & Sadowska, J. (2023) · Nutrients · doi:10.3390/nu15081871 · Cited by 4
“Drugs applied to treat schizophrenia and bipolarity are an additional factor enhancing or generating metabolic disorders [10,11] and contribute to, inter alia, insulin resistance [12] and its consequences manifested as body weight gain, type 2 diabetes, hyperlipidemia, etc.”
BackgroundPreliminary Examination of Olanzapine and Diet Interactions on Metabolism in a Female Macaque
Bethea, C. L. (2014) · Journal of Endocrinology and Diabetes · doi:10.15226/2374-6890/1/2/00112 · Cited by 4
“[43] demonstrated that short-”
Kovács, D. K., Hegedűs, C., Kiss, R., Sári, R. Z., Németh, J., Szilvássy, Z., & Peitl, B. (2015) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-015-1091-8 · Cited by 4
“However, olanzapine is able to induce metabolic derangement in the absence of obesity (Newcomer et al. 2002; Teff et al. 2013).”
BackgroundResultInfluentialZheng, L., Xiong, Y., Nie, W., & Si, T. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120462 · Cited by 3
A Possible Role of Akkermansia muciniphila in the Treatment of Olanzapine-Induced Weight Gain
Bertossi, F. (2024) · Cureus · doi:10.7759/cureus.55733 · Cited by 5
“Metabolic dysregulation has been seen in patients after long-term olanzapine treatment in the absence of overt weight gain in both clinical and preclinical studies [50-52].”
BackgroundMutual effects of gestational diabetes and schizophrenia: how can one promote the other?: A review
Ghamri, K. A. (2024) · Medicine · doi:10.1097/md.0000000000038677 · Cited by 3
“[84,85] Atypical antipsychotics can also alter insulin response to glycemia changes by antagonizing the serotonergic (5HT(2)) and dopamine D(2)-like receptor-mediated release of insulin.”
BackgroundInfluentialAdiposity and Cardiometabolic Risk in Children With and Without Antipsychotic Drug Treatment
Nicol, G. E., Fuentes, L. D. L., Riek, A. E., Bernal‐Mizrachi, C., Lenze, E. J., Miller, J. P., Schweiger, J. A., Yingling, M. D., Huang, V. J., Dixon, D. J., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2119 · Cited by 3
Watanabe, A., Fukui, N., Suzuki, Y., Motegi, T., Igeta, H., Tsuneyama, N., & Someya, T. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.03.012 · Cited by 3
“[3] administered olanzapine, aripiprazole or placebo to healthy subjects (n=10, each group) for 9 days.”
BackgroundInfluentialCan metabolic side effects of antipsychotics be reversed by lifestyle changes?
Bolger, A., Verdolini, N., & Agius, M. (2014) · PubMed · Cited by 3
Antipsychotic use during pregnancy and risk of gestational diabetes: an updated meta-analysis
Zhang, H., Zhang, X., Wei, L., Chen, S., Fan, Y., & Huang, L. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120633 · Cited by 2
Lee, S., Kim, M., Trott, M., Siskind, D. J., & Kim, J. H. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261456190 · Cited by 2
“Given that AIWG is mechanistically linked to insulin resistance and dysregulated appetite control, GLP-1RAs represent a biologically plausible strategy to counteract these metabolic effects (Albaugh et al., 2011; Ebdrup et al., 2012; Teff et al., 2013).”
Perphenazine-Associated Hyperosmolar Hyperglycemic State
Maust, M. S., Muramatsu, R. S., Egan, K., & Ahmed, I. I. K. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000359 · Cited by 2
“To the Editors: A ntipsychotic medications are associated with glucose elevation, insulin resistance, and diabetes even independent of weight gain.(1,2) Hyperglycemic crises have also been attributed to the use of certain antipsychotics.”
BackgroundHasni, D., Sona, A., Anissa, M., & Heppy, F. (2020) · Jurnal Kedokteran dan Kesehatan · doi:10.24853/jkk.16.1.6-11 · Cited by 2
Han, J. H., Kim, J. M., & Yoo, H. J. (2024) · Journal of korean Academy of Child and Adolescent Psychiatry · doi:10.5765/jkacap.230057 · Cited by 2
“However, aripiprazole use in children and adolescents is associated with certain side effects such as increased appetite, weight gain, elevated fasting blood glucose, dyslipidemia, and increased insulin resistance [16].”
BackgroundExploring the effects of an insulin challenge on neuroimaging outcomes: A scoping review
Stogios, N., Wu, S., Hahn, M., Emami, Z., Navagnanavel, J., Korann, V., Prasannakumar, A., Remington, G. J., Graff‐Guerrero, A., & Agarwal, S. M. (2025) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2025.101187 · Cited by 3
Food and nutrition insecurity among individuals with schizophrenia and related psychotic disorders
Compton, M. T. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.06.023 · Cited by 3
Increased Risk of Diabetes Among 6–24-Year-Olds Using Second Generation Antipsychotics
Xing, S., & Lee, T. A. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0072 · Cited by 2
“however, recent evidence suggests that SGA’s effects on glucose metabolism and insulin dysregulation can occur in the absence of any weight gain (Scheen and De Hert 2007; Teff et al. 2013; Ebdrup et al. 2014; Raebel et al. 2014).”
Expectant management of a parturient with serotonin syndrome: A case report
Hammond, B., Straube, L. E., & Cobb, B. T. (2020) · Obstetric Medicine · doi:10.1177/1753495x20971155 · Cited by 2
Diabetes mellitus in patients using psychotropic medications: How does it work?*
Kosmalski, M., Różycka-Kosmalska, M., Sikora, J., & Pietras, T. (2021) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0014.9330 · Cited by 2
Boyle, K., Boyle, J. G., Fisher, M., & McKay, G. (2014) · Practical Diabetes · doi:10.1002/pdi.1891 · Cited by 2
Schizophrenia and Related Psychoses
(2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg001.pub2 · Cited by 2
Nadalin, S., Peitl, V., Karlović, D., Sučić, P., Zatković, L., & Buretić‐Tomljanović, A. (2023) · Archives of Psychiatry and Psychotherapy · doi:10.12740/app/163305 · Cited by 1
Ponte, C. D., & Dang, D. K. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch19 · Cited by 1
Nkondo-Ndaba, M. P., Joubert, P., Ballyram, T., & van Rensburg, C. J. (2022) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v28i0.1772 · Cited by 3
Amini, K., Motallebi, M., Bakhtiari, K., Hajmiri, M. S., Zamanirafe, M., Sharifikia, M., Ranjbar, A., Keshavarzi, A., Mirjalili, M., & Mehrpooya, M. (2024) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2907 · Cited by 2
“Supporting this hypothesis, some reports demonstrate clinically significant glucose and lipid abnormalities during treatment with certain atypical antipsychotics in the absence of drug ‐ induced weight gain (Kang & Lee, 2015; Lauressergues et al., 2010; Newcomer et al., 2002; Teff et al., 2013).”
Mécanismes des effets diabétogènes des médicaments antipsychotiques
Fève, B. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30070-5 · Cited by 1
Hyperglycemia Secondary to Nondiabetic Conditions and Therapies
Lebovitz, H. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00042-1 · Cited by 1
Pawar, A. (2013) · International Journal of Pharmaceutical and Biological Archive
The Use of Nervous System Drugs and the Risk of Fractures in Old Adults
Nurminen, J. (2014) · UTUPub (University of Turku) · Cited by 1
Rehabilitation to prevent premature mortality among people with serious mental illness
Rosenbaum, S. (2013) · International Journal of Therapy and Rehabilitation · doi:10.12968/ijtr.2013.20.11.528
Preventive Health Care among Canadian Adults with Schizophrenia and Related Disorders
Beck, C. A. (2014) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/27428
Determinantes del aumento de peso producido por los antipsicóticos: un estudio de cohortes
Velasco, V. (2016) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/16294 · Cited by 2
Az inzulinrezisztencia farmakológiai befolyásolhatóságának lehetőségei
Kovács, D. K. (2015) · University of Debrecen Electronic Archive (University of Debrecen)
Reeves, G. M., & Sikich, L. (2017) · Contemporary Endocrinology · doi:10.1007/978-3-319-68192-4_37
Investigating Antipsychotic Drug-induced Impairment of Central Energy Homeostasis
Kowalchuk, C. (2019) · TSpace (University of Toronto)
Ponte, C. D., & Dang, D. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch21
Can we run away from the metabolic side effects of antipsychotics?
Akcan, M., & Wright, D. C. (2025) · Translational Exercise Biomedicine · doi:10.1515/teb-2025-0016
Drug-induced glucose metabolism disorders: A disproportionality analysis based on the FAERS databasePreprint
Zhang, Z., Li, Q., Huang, T., Yang, X., Du, X., Deng, X., Wang, S., & Zhou, J. (2025) · medRxiv · doi:10.1101/2025.08.26.25334521
Laemango, A. M., Begna, M. B., Masebo, D. T., Anshebo, D. L., Woyesa, S., & Funga, M. L. (2025) · PLoS ONE · doi:10.1371/journal.pone.0333284
David Kovilraj, S., J, S. S. G., Nalini, S., & Kalavalli, M. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07408-9
“These effects are associated with significant elevations in postprandial insulin, glucagon-like peptide 1 (GLP-1), and glucagon, along with increased insulin resistance [12].”
Association of taking psychotropic drugs and weight gain
Κοκάρας, Κ. Ι., & Κοκάρας, Κ. Ι. (2024) · University of Thessaly Institutional Repository (University of Thessaly) · doi:10.26253/heal.uth.39651
Interplay between Schizophrenia, Diabetes, and Cardiovascular DiseasePreprint
Aluri, B. S. (2026) · doi:10.58445/rars.3589
Wu, S. (2025) · TSpace (University of Toronto)
The Effects of Antipsychotics on Central Lipid-Mediated Regulation of Glucose Metabolism
Au, E. (2023) · TSpace (University of Toronto)
Weng, S., Lin, J., & Chai, D. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1729264 · Cited by 1
Hyperglycemic Emergencies in Critically Ill Patients
Patel, M. S., Khan, S., Horng, M., Khan, S., & Thosani, S. (2026) · Springer eBooks · doi:10.1007/978-3-319-74698-2_210-1
You, R., Safargar, M., Prabahar, K., Kord-Varkaneh, H., & Xiang, J. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02223-y
“This metabolic pattern implies that olanzapine may place stress on glucose regulatory systems, leading to increased insulin secretion in an attempt to preserve normoglycemia, particularly during short-to intermediate-term exposure [49, 50].”
Antipsychotic Drug-Induced Insulin Resistance: A Narrative Literature Review
Dąbrowska, A., & Zgliczyński, W. (2025) · Wiedza Medyczna · doi:10.36553/wm.177
“…did not gain weight but developed glycemic disturbances (e.g., in OGTT) after taking antipsychotics (15), even in healthy volunteers (16), and after a single dose of an antipsychotic such as olanzapine (17), but also in certain cases after ar - ipiprazole, considered "metabolically sparing" (18).”
Ramírez‐Herrera, O., D’Espessailles, A., Burrone, M. S., & Santander, N. G. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118266
Cheung, N., Cheung, H. K., Yu, Y. W., & Tsang, Y. C. Y. (2026) · Research Square · doi:10.21203/rs.3.rs-10656343/v1
Luo, C., Qing, G., Zhang, J., Wan, H., Xiong, S., Zhou, Y., Yan, K., & Xiong, Y. (2026) · The International Journal of Psychiatry in Medicine · doi:10.1177/00912174261474760
Werla, A., Kocik, A., Łapot, M., Wiak, B., Raczek, W., Wywiał, A., Spaczyńska, K., Kropiwnicka, A., Motaouakkil, Y., Racki, E., et al. (2026) · African Journal of Biomedical Research · doi:10.69980/hgmpe740
Kaczynski, M., Zureikat, R. M., Kaczynski, M. R., Sitarz, R., & Karakuła‐Juchnowicz, H. (2026) · Biomedicines · doi:10.3390/biomedicines14091957
“…POMC activation in the arcuate nucleus [33,34]; hepatic and peripheral effects contribute to insulin resistance independently of weight gain [40,41]; and sedation with D2-related effects contributes to reduced physical activity, which is markedly lower in this population than in matched…”
Akcan, M., Jeromson, S., Baranowski, B. J., Bellucci, A., Trang, S., Eisner, K., Babicki-Moore, A., Alfares, H., Arbeau, M., Medak, K., et al. (2026) · The FASEB Journal · doi:10.1096/fj.202602558r
“In this regard, we have shown that olanzapine treatment acutely increases serum glucagon in mice [17, 26–29], an effect also shown in humans, where OLZ increases glucagon independent of weight gain [30, 31].”
Hypertriglyceridemia: Causes, Consequences, Diagnosis, and Management
Qi, S., Chen, W., Chen, K., Yang, S., Wang, S., Ni, T., Xu, D., Mao, E., Chen, E., & Chen, Y. (2026) · MedComm · doi:10.1002/mco2.70956
Effects of Antipsychotics on Skeletal Muscle Molecular Pathways: A Systematic Review
Burghardt, K. J., Jaiswal, R., Zeineddine, M., & Yi, Z. (2026) · Life · doi:10.3390/life16111826
Metabolic Syndrome Among Inpatients With Schizophrenia: Prevalence and Clinical Correlates
汤瑁, Chang, S.-H., Qian, H., Zhang, C.-Y., & Zhong, B. (2026) · ALPHA PSYCHIATRY · doi:10.31083/ap56362
Ferreira, V., Alén, R., Koller, D., Povo‐Retana, A., Grajales, D., Sánchez‐Carro, Y., Boscá, L., Izquierdo, M., López-García, P., Garcia-Portilla, P., et al. (2026) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-026-01250-7
Raben, A. T., Marshe, V. S., Chintoh, A., Gorbovskaya, I., Müller, D. J., & Hahn, M. K. (2018) · doi:10.3389/fnins.2017.00741.s001
Metadata
- Authors
- Teff, K. L., Rickels, M. R., Grudziak, J., Fuller, C., Nguyen, H.-L., & Rickels, K.
- Affiliations
- Monell Chemical Senses Center (US)
- University of Pennsylvania (US)
- Corresponding author
- Teff, Karen L.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-08-15
- Volume
- 62
- Issue
- 9
- Pages
- 3232-3240
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3749337
- OpenAlex
- W2126815601
- Cited by
- 195
- References
- 51
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 14 · 2023: 10 · 2022: 14 · 2021: 15 · 2020: 12 · 2019: 12 · 2018: 21 · 2017: 15 · 2016: 18 · 2015: 19 · 2014: 15 · 2013: 5
- FWCI
- 13.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- University of Pennsylvania
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 19525, R01DK084383, DK084383, P30DK019525)
- National Center for Research Resources (UL1RR024134)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- atypical antipsychotics, insulin resistance, olanzapine, aripiprazole, postprandial insulin, glucagon-like peptide-1, glucagon, glucose disposal, insulin sensitivity, metabolic side effects, weight gain, appetite, hyperinsulinemic-euglycemic clamp, meal challenge
- MeSH terms
- Aripiprazole, Olanzapine, Adult, Mental Disorders, Benzodiazepines, Eating, Female, Humans, Insulin Resistance, Male, Piperazines, Antipsychotic Agents, Quinolones, Weight Gain, Postprandial Period, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.